目的 觀察重組人表皮生長因子（rhEGF）凝膠聯(lián)合他克莫司軟膏外用對激素依賴性皮炎（HDD）的臨床療效和安全性。方法 選取2014年3月－2016年1月湖北省黃石市愛康醫(yī)院皮膚科診治的面部HDD患者108例，隨機(jī)分為他克莫司軟膏對照組和rhEGF凝膠聯(lián)合他克莫司軟膏治療組，每組54例。對照組外敷他克莫司軟膏，2次/d，治療組在對照組基礎(chǔ)上加用rhEGF凝膠，2次/d。連續(xù)治療4周，比較兩組臨床療效、復(fù)發(fā)率和不良反應(yīng)。結(jié)果 治療前兩組表皮含水量、表皮油脂含量和表皮經(jīng)皮水分丟失（TEWL）值無顯著差異；治療后兩組表皮含水量和表皮油脂含量顯著升高（P<0.05、0.01），TEWL值顯著減低（P<0.05、0.01），但治療組對表皮含水量和表皮油脂含量的升高作用和對TEWL值的減低作用顯著優(yōu)于對照組（P<0.05）。治療組有效率為90.7%，顯著高于對照組的72.2%（P<0.05）。隨訪6個月，治療組復(fù)發(fā)率為11.1%，顯著低于對照組的26.0%（P<0.05）。治療組不良反應(yīng)發(fā)生率為3.7%，對照組的5.6%，兩組比較無顯著性差異。結(jié)論 rhEGF凝膠聯(lián)合他克莫司軟膏治療面部HDD，臨床療效顯著、使用安全。

Objective To detect the clinical efficacy of Recombinant Human Epidermal Growth Factor (rhEGF) Gel combined with tacrolimus on facial hormone dependent dermatitis (HDD) and security. Methods Totally 108 facial HDD patients from Huangshi Aikang Hospital in Hubei province were enrolled, randomly divided into two groups. The control group (n=54) was treated with tacrolimus (twice daily), the treatment group was treated with rhEGF Gel and tacrolimus (twice daily) for 4 weeks. The clinical efficacy, recurernce rate, and adverse reactions were compared. Results There was no significant difference of skin moisture content, skin oil content, and TEWL values between the two groups before treatment. The increasing of skin moisture and skin oil content and decreasing of TEWL values in observation group was better than that in control group after treatment (P<0.05). The clinical efficacy was 90.7% in observation group, which was better than that of 72.2% in control group (P<0.05). The recurrence rate in observation group was 11.1%, which was significantly lower than that of 26.0% in control group (P<0.05). The incidence of adverse reactions was 3.7% in the observation group and 5.6% in the control group. There was no significant difference of adverse reaction rates between the two groups. Conclusion rhEGF Gel combined with tacrolimus showed significantly clinical efficacy and safety in treatment of facial HDD.